about us

press release

contact

Search

Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

Biotechnology News Magazine is one of the industry’s leading sources for biotech industry news!
Biotechnology News Magazine reports the latest biotech, pharma, FDA updates, biotechnology clinical trials, biotechnology mergers, biotechnology acquisitions, biotechnology funding, articles of interest and other important news.

Biotech executives, investors, and other allied health professionals have access to Biotechnology News Magazine through a complimentary subscription. Furthermore, as patients become more pro-active in researching various medical diseases and conditions, we are proud to boast they are subscribers of our publication as well.

We hope you find value in Biotechnology News Magazine’s overall purpose and objectives.

Biotechnology News Magazine is a fast, 1,2,3, easy read!

LEARN MORE.

Visit our sister publication site
Medical Device News Magazine

Medical Device News Magazine welcomes guest byline articles to inform and educate medical specialists, device industry executives, other allied health professionals, investors and more.

Articles from key opinion leaders provide great insight and in some cases, are superior over standard press releases! We invite guest contributions! Contact  mdnewsmagazine@infomeddnews.com

Latest Biotech Industry News

BRIM Biotechnology & Ora Announce New Partnership

BRIM Biotechnolgy notes the new partnership builds on the success of our previous collaboration for Phase 2 trials and will help to speed the progression of BRM421 through late-stage clinical development toward regulatory filing.

Cytel Designed & Led TOGETHER Trial Wins Society of Clinical Trial’s David Sackett Trial of the Year Award

TOGETHER trial has enrolled over 6000 patients in 22 research sites in Brazil.  It is now expanding to Pakistan and South Africa, Rwanda, DRC, and Vietnam.

TECHKON Offers E-Health Technology Patent for Smartphone based Medical Rapid Test

Depending on the type of medical parameter to be analyzed, the user puts a drop of saliva, blood, or any other body fluid on a card that contains a bio-/ chemical reaction substance and separation mechanism.

DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients

DiNAQOR DiNAMIQS offers comprehensive range of biomanufacturing services, GMP-compatible process development, quality control and analytical development

Novo Holdings Portfolio Company F2G Enters Strategic Collaboration with Shionogi

Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections advises Novo Holdings.

AffyXell Expands its Strategic Partnership with GenScript ProBio

AffyXell and GenScript ProBio partnership covers process development and production of viral vectors required for the production of AffyXell’s future cell therapy products.

BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.

With 510(k) clearance from the U.S. Food and Drug Administration, the new BD COR™ MX instrument is a new analytic instrument option for the BD COR™ System.

Myrtelle Announces Expansion of Its Pipeline with a Novel Gene Therapy Program for Pelizaeus-Merzbacher Disease

Myrtelle notes the gene therapy strategy uses a nonpathogenic recombinant adeno-associated virus as a vector to deliver a gene silencing microRNA (miRNA) directly to the central nervous system to target oligodendrocytes. The miRNA is intended to reduce toxic levels of proteolipid protein 1 (Plp1), the underlying cause of PMD.

GenNext Technologies Introduces Protein Footprinting Products to Japan through Kiko Tech Co., LTD.

GenNext Technologies & Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation (Fox™) Protein Footprinting Systems.

Verseon Delivers Breakthrough Once Predicted by Steve Jobs

Chief Technology Officer of Verseon Sangtae Kim, a member of the US National Academy of Engineering, says the platform is far more sophisticated than the ‘AI systems’ of other drug developers, as it enables Verseon to design the entirely new chemical structures needed to fight currently untreatable diseases.

Avantor and Cytovance Biologics Collaborate to Accelerate Plasmid DNA Development for Biopharma Customers

Collaboration will accelerate plasmid optimization and sourcing services for new and existing viral vector and mRNA-based vaccine and therapeutic customers notes Avantor.

KSL Diagnostics and University at Buffalo Show Reports Correlation Between COVID-19 Antibody Levels and Virus Neutralization at Congress of Clinical Rheumatology

KSL Diagnostics: The aim of the study was to compare the semi-quantitative titers of a laboratory-developed SARS-CoV-2 spike antibody assay against the industry-standard plaque reduction neutralization test (PRNT) to determine if a specific circulating antibody titer is needed for optimal virus deactivation.

Virax Biolabs Receives Ethical Approval for its Virax Immune COVID-19 Analytical Performance Study from the SBEBO Foundation for the Assessment of Ethics of Biomedical Research

The Analytical Performance Study will evaluate the technical performance of the Virax Immune COVID-19 Flow Cytometry Kit notes Virax Biolabs.

HepaTx Announces the Issuance of US Patent entitled “Methods and Composition for Producing Hepatocyte-Like Cells”

HepaTx is a biotechnology company focused on innovative off-the-shelf cell therapies to treat late-stage liver disease.
Load more
Load more

Noteworthy Views & Opinions from Our Experts

Reduced Nicotine Content Cigarettes: A Bridge to Somewhere: By James A Mish Chief Executive Officer 22nd Century Group

Is willpower the answer to quitting cigarettes? Read what Chief Executive Officer James A. Mish of 22nd Century Group has to say.

Citius Pharmaceuticals Growth Strategy: Two Phase 3 Assets & Diversified Pipeline: By Leonard Mazur Chairman & CEO

Mr. Mazur provides details about Citius Pharmaceuticals, recent developments, and a great deal more. A must-read article.

Temporary Labs and Testing Clinics-The Covid Response from Flooring Manufacturer SelecTech

Thomas Ricciardelli, President of SelecTech: "While flooring is but one part of a temporary facility, it’s a critical one. And thankfully, the development of vaccines and better therapeutics have slowed the Covid pandemic down so temporary facilities aren’t needed. Still, it’s nice to know that in a time of crisis, there exists the resources—including flooring—to create these types of facilities in fairly short order." Read on.

Dr Juan Jofre PhD: The Growing Interest in Coliphages & Their Proven Effectiveness As Needed Viral Indicators In Water Quality Control

Dr Juan Jofre PhD writes, "In the late 1960s, it became clear that bacterial indicators used today to assess microbiological water quality are ineffective in predicting viruses' presence in water, sludge, or food matrices. Therefore, adequately detecting and monitoring viral contamination in aquatic environments became evident." Read what he has to say.

FDA Updates

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

LogicBio Therapeutics initiates activities to resume dosing.

Dimerix Reports FDA IND Approval for Phase 3 Study of DMX-200 in FSGS

FDA IND approved for ACTION3 Phase 3 clinical study, paves the way for patient recruitment in the United States reports Dimerix.

AlloVir Reports FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir advises Posoleucel’s third RMAT designation marks an unprecedented regulatory distinction among cell and gene therapies.

BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

BioCardia notes the first part of the clinical trial will evaluate increasing doses of the NK1R+ MSCs and the optimal dose will be taken to Phase II in a randomized study in adult patients recovering from ARDS due to COVID-19.
Load more

Acquisitions & Mergers

Biotium Announces Acquisition of CAT5™ FFPE RNA/DNA Extraction Technology from Cell Data Sciences

RNAstorm™ and DNAstorm™ RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors notes Biotium.

DCN Dx Acquires Microbiological Testing Products Company Biomed Diagnostics

DCN Dx advises the acquisition expands DCN Dx's footprint in the point-of-use testing and sampling markets in both human and veterinary verticals.

Genovac Acquires the Carterra LSA® Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services

Genovac becomes Carterra’s 100th LSA placement throughout the world.

Samsung Biologics Completes Full Acquisition of Samsung Bioepis

Samsung Biologics notes accelerated growth is expected in biosimilars and future novel therapeutics R&D
Load more

Funding

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology

OncoHost said the funding will go towards expanding OncoHost’s ongoing multicenter PROPHETIC trial.

Aspen Neuroscience Announces $147.5 Million Series B Financing

Will fund clinical trials of Aspen Neuroscience 1st iPSC-derived autologous dopamine neuron replacement for Parkinson's Disease.

FACIT Invests in OICR’s Groundbreaking Approaches to Integrated Drug Discovery & Cancer Informatics

FACIT notes the early-stage capital positions science and intellectual property for Ontario economic impact.

iXensor Receives Strategic Investment from Rohto Pharmaceutical with A Separate Technology Licensing Agreement

PixoTech® licensing shifted in as iXensor's new growth engine to meet self-testing strong demand in the post-pandemic era.
Load more

Clinical Trials, Studies, Data

University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder

The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug-using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the FDA.

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

“The data presented today reinforce the important role that the Percepta Nasal Swab classifier may play in helping to guide next steps for current and former smokers with lung nodules – including those who may be considered low risk based on their smoking history burden,” said Giulia C. Kennedy, Ph.D., Veracyte’s global chief scientific officer and chief medical officer.

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022

There is potential for PH-894 to play a role in boosting the potency of the next generation of CAR-T cell products to enhance adoptive cell therapy for solid tumors without using genetic manipulation notes Phio Pharmaceuticals.
Load more

Executives on the Move

Abraham Verghese MD Appointed to the Board of Directors of Athos Therapeutics

"Abraham Verghese MD is a highly distinguished physician, humanist, administrator, and adviser," said Allan Pantuck, MD, MS, FACS, Chairman & CMO.

Johan Baeck MD Appointed EVP and CMO of Promontory Therapeutics

Johan Baeck MD joins Promontory Therapeutics from Jounce Therapeutics where he served as Senior Vice President, Clinical Development and Medical Affairs.

Sphere Fluidics Strengthens Commercial Team

The appointments form part of broader ongoing recruitment plans to support expanded operations and product development notes Sphere Fluidics.

Pierre Legault Appointed Egle Therapeutics Chairman and Board Member

Pierre Legault provides extensive experience over 35 years in leadership roles at leading companies across the biotech and pharmaceutical sector.
Load more

Health / Lifestyle Articles

Articles of Interest

Market Reports

Looking to advertise in a Biotech Magazine? Contact us today at BNM@bnmag1.com or 561.316.3330.

© Copyright 2021 Biotechnology News Magazine, a division of PTM Healthcare Marketing, Inc.